Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,231 | 10,378 | 13,032 | 1,764 | 1,628 |
| TOTAL | $7,849 | $11,023 | $13,972 | $2,328 | $2,126 |
| Non-Current Assets | |||||
| PPE Net | 359 | 207 | 223 | 242 | 263 |
| Other Non-Current Assets | 48 | 48 | 48 | 48 | 48 |
| TOTAL | $407 | $255 | $271 | $290 | $311 |
| Total Assets | $8,255 | $11,278 | $14,243 | $2,618 | $2,437 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 630 | 1,196 | 509 | 1,151 | 632 |
| Accrued Expenses | 1,058 | 206 | 771 | 626 | 205 |
| TOTAL | $1,871 | $1,459 | $1,327 | $1,884 | $1,005 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,882 | 2,608 | 2,344 | 2,081 | 1,825 |
| TOTAL | $3,162 | $2,903 | $2,654 | $2,405 | $2,039 |
| Total Liabilities | $5,034 | $4,362 | $3,980 | $4,289 | $3,044 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 860 | 767 | 763 | 390 | 312 |
| Common Shares | 23 | 23 | 23 | 12 | 9 |
| Retained earnings | -160,758 | -156,544 | -152,465 | -149,261 | -144,264 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $3,222 | $6,917 | $10,263 | $-1,672 | $-607 |
| Total Liabilities And Equity | $8,255 | $11,278 | $14,243 | $2,618 | $2,437 |